Posts Archive

NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902

NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma

NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM

NCT04895410: Phase 1 -IV Lemzoparlimab +/- Oral/IV Dex plus Oral/IV/SC Anti-Myeloma Regimens

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

NCT04756726: Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma

NCT04093596: Phase 1 - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma (UNIVERSAL)

NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM

NCT04052880 : Phase 2 - SubQ Dara + Dose-Atten. Bortezomib, Lenalidomide, Dex New MM >70 years

NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)

NCT04036461: Phase 1 - A Study of CC-99712, a BCMA Antibody-Drug Conjugate in relapsed MM

NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2

NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)